Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. USO
2. MSFT
3. SPY
4. META
5. COST
6. MU
7. IONS
8. RXT
9. AAPL
10. CME

Go back to Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab
(NASDAQ: APVO) Delayed: 3.96 -0.54 (12%)
Previous Close $4.50    52 Week High $4.33 
Open $4.00    52 Week Low $1.80 
Day High $4.00    P/E N/A 
Day Low $3.68    EPS $0.00 
Volume 129,439